Ocugen, Inc. (NASDAQ:OCGN) shares are trading higher Friday after the company announced it has received approval to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of its Phase 1/2 study.
The Details:
Ocugen said the Data and Safety Monitoring Board for the Phase 1/2 ArMaDa clinical trial for OCU410 has approved to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of the study.
“The positive DSMB review for the first modifier gene therapy for GA significantly builds on the favorable safety and tolerability profile exhibited by OCU410. We are very enthusiastic about the potential of OCU410 as a one-time treatment for life with a single sub-retinal injection,” said Huma Qamar, M.D., MPH, Chief Medical Officer of Ocugen.
The company ...